The latest FDA advisory panel vote on broader peptide compounding access, including BPC-157 and related compounds, has pushed Hims & Hers Health (HIMS) back into focus for investors watching regulatory catalysts.

For context, Hims & Hers Health’s recent FDA catalyst comes after a period where the share price has fallen 14.1% over the past 30 days and 15.9% year to date, while the 1 year total shareholder return is down 51.3% and the 3 year total shareholder return is up more than 3x. Recent momentum has cooled after a very strong earlier run.

If regulatory risk and growth stories are on your mind, it can help to compare Hims & Hers Health with other healthcare technology plays and see what the market is rewarding right now through 39 healthcare AI stocks

Hims & Hers Health now trades slightly below the average analyst target, yet internal fair value work still points to a much deeper discount. Is the market’s caution on regulation and governance keeping the stock cheaper than the fundamentals imply?

Most Popular Narrative: 84% Undervalued

The most followed narrative on Hims & Hers Health pegs fair value at $173.02 per share, far above the recent $28.09 close, which frames a very large upside gap in the model.

Over the long term (10yrs), Hims & Hers has an unusually large addressable market ahead of it. The company’s growth is driven by three reinforcing dimensions:

• Expanding market size, as digital healthcare adoption continues to grow globally

• Category expansion, including new offerings such as hormonal health, longevity, and sleep

• International scaling, with multiple geographies already in the pipeline (e.g. Brazil, Australia)

• Growth inside of the current categories. Together, these form a multi-dimensional growth model that provides durable tailwinds for many years.

According to Deep_Insights, this valuation leans heavily on compounding revenue growth, rising margins and a premium earnings multiple that is usually reserved for market leaders. It examines which specific growth drivers and profitability assumptions would need to align to support a fair value far above today’s price, and how that contrasts with current market caution around regulation and competition.

Result: Fair Value of $173.02 (UNDERVALUED)

However, this Hims & Hers Health narrative could be challenged if regulatory views on compounded peptides tighten further, or if margin progress stalls against rising investment and competition.

Next Steps

If the mixed sentiment around Hims & Hers Health leaves you undecided, now is a good time to review the underlying drivers and make your own assessment with the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Hims & Hers Health?

If you want to balance your view on Hims & Hers Health, use these curated ideas to spot other opportunities before the market fully pays attention.

• Target potential mispricings by scanning 49 high quality undervalued stocks and see which companies currently trade at a discount to their fundamentals.
• Strengthen the defensive side of your portfolio by focusing on companies in the solid balance sheet and fundamentals stocks screener (49 results) that prioritize financial resilience.
• Review the screener containing 20 high quality undiscovered gems to find underfollowed stocks with strong fundamentals that may not be on most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.